Global Breast Biopsy Market Trends, Forecast Report 2025-2037
Breast Biopsy Market size is expected to grow from USD 3.4 billion to USD 7.71 billion, exhibiting a CAGR of more than 6.5% during the forecast timeline, between 2025 and 2037. In the year 2025, the industry size of breast biopsy is estimated at USD 3.58 billion.
The market growth is mainly due to increasing cases of breast cancer. According to the World Health Organization (WHO), by the end of 2020, 711 million women had been diagnosed with breast cancer in the past 5 years, making it the most common cancer in the world. In addition, government initiatives around the world to develop and implement new screening programs, raise awareness of treatment options, and organize free camps are expected to be the driving force for the global market development.
Breast Biopsy Sector: Growth Driver and Challenges
Growth Driver
- Increasing Consumption of Unhealthy Foods- Breast cancer is increasing globally due to the increasing consumption of unhealthy and fried foods by women worldwide. One study found that women who regularly ate fried food were 4.5 times more likely to develop breast cancer than other women her age, with a very significant association between highly fried foods and the risk of breast cancer.
- Technological Advances in Breast Biopsy Equipment: Technological advances in breast biopsy devices have led to the development of more precise and less invasive procedures. For example, 3D mammography is becoming increasingly popular because it provides higher-resolution images that can detect smaller lesions. One study found that 3D mammography was associated with a 41% increased chance of detecting invasive breast cancer compared with traditional 2D mammography.
- Raise Awareness About Breast Cancer Screening: Growing awareness of the importance of early detection and diagnosis of breast cancer, through breast cancer screening, leading to an increase in the number of women undergoing breast biopsy procedures. According to a survey, nearly 75% of women aged 40 and over said they had a mammogram in the past two years.
- Increased Spending on Health: Increasing healthcare costs worldwide are driving the growth of the global breast biopsy market. According to a study, global health expenditure was valued at USD 7.1 trillion in 2019 and is expected to reach USD 12.8 trillion by 2026. As healthcare costs continue to rise, more resources will be allocated to breast cancer screening and diagnosis, which will lead to an increase in demand for breast biopsy procedures.
Challenges
- High Cost of Breast Biopsy Procedures – Breast biopsy procedures can be expensive, particularly in countries where healthcare costs are high. This can make it difficult for some patients to access the procedure, leading to delays in diagnosis and treatments.
- Lack of Awareness and Education
- Fear and Discomfort
Breast Biopsy Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 3.4 billion |
|
Forecast Year Market Size (2037) |
USD 7.71 billion |
|
Regional Scope |
|
Breast Biopsy Segmentation
End Users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers)
The hospital segment in the breast biopsy market is estimated to hold around 40% revenue share by 2037. The growth of this segment can be attributed to large number of patients requiring breast biopsies and hospitalization for surgery or treatment. Hospitals are also experiencing remarkable growth in numbers. For example, in 2022, there are about 6,100 hospitals in the United States.
Product (Biopsy Needles, Biopsy Tables, Biopsy Wires)
The biopsy needle segment is set to hold 30% share of the global breast biopsy market by the end of 2037, impelled by increasing demand for breast biopsy procedures, including the use of biopsy needles. The growing awareness of the importance of breast biopsy procedures, including the use of biopsy needles.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBreast Biopsy Landscape – Regional Scope
APAC Market Forecast
The breast biopsies market in Asia Pacific is expected to hold around 35% share by the end of 2037. The growth of the region is due to increase in the percentage of the aging population. As older women have a higher risk of breast cancer. Also, health organizations are increasingly promoting breast cancer screening programs, including mammograms and breast biopsies.
North America Market Statistics
The breast biopsy market in the North America is expected to account for 25% revenue share by 2037, attributed to increasing technological advancement in breast biopsy technology in the region. There have been significant advances in the design and function of biopsy needles and other biopsy devices in North America, making breast biopsies more precise and less invasive. This has led to an increase in demand for breast biopsy procedures in the region. All insurance plans in North America cover breast biopsy procedures, making the procedure easier for patients to access, leading to increased demand.
Companies Dominating the Breast Biopsy Landscape
- Hologic, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Danaher Corporation
- BD (Becton, Dickinson, and Company)
- Cook Medical LLC
- Argon Medical Devices, Inc.
- B. Braun Melsungen AG
- C.R. Bard, Inc.
- Devicor Medical Products, Inc.
- Cardinal Health, Inc.
In the News
- Hologic Inc, Hologic announced that its subsidiary, Biotheranostics, received a positive coverage determination from Medicare for Its Breast Cancer Index genomic test. The Breast Cancer Index test is used to predict the likelihood of recurrence in early-stage, hormone receptor-positive breast cancer patients.
- BD (Becton, Dickinson, and Company). BD announced the launch of the BO Intevia 1mL two-step disposable autoinjector, which is used for the subcutaneous injection of biological drugs. The device is designed to enhance patient experience and medication adherence by providing a reliable, easy-to-use, and customizable Infection experience. The BD Intevia autoinjector is part of the company's broader portfolio of products for drug delivery and administration.
Author Credits: Radhika Pawar
- Report ID: 747
- Published Date: Jan 17, 2025
- Report Format: PDF, PPT
